Virtus ETF Advisers LLC Verastem, Inc. Transaction History

Virtus ETF Advisers LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.83 $70,302 - $126,130	-68,924 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.06 - $2.1 $4,323 - $8,565	-4,079 Reduced 5.59%	68,924 $97,000
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $57,514 - $89,779	28,056 Added 62.42%	73,003 $150,000
Q3 2021 Nov 15, 2021	SELL	$2.54 - $4.07 $5,953 - $9,540	-2,344 Reduced 4.96%	44,947 $138,000
Q2 2021 Aug 10, 2021	SELL	$2.57 - $4.85 $218,473 - $412,293	-85,009 Reduced 64.25%	47,291 $192,000
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $4,444 - $6,595	2,339 Added 1.8%	132,300 $327,000
Q4 2020 Feb 12, 2021	SELL	$1.15 - $2.4 $51,933 - $108,384	-45,160 Reduced 25.79%	129,961 $277,000
Q3 2020 Nov 13, 2020	SELL	$1.11 - $1.68 $26,516 - $40,133	-23,889 Reduced 12.0%	175,121 $212,000
Q2 2020 Aug 05, 2020	BUY	$1.69 - $4.2 $336,326 - $835,842	199,010 New	199,010 $342,000
Q4 2018 Feb 05, 2019	SELL	$3.23 - $7.01 $266,662 - $578,731	-82,558 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$6.86 - $9.97 $415,921 - $604,481	-60,630 Reduced 42.34%	82,558 $599,000
Q2 2018 Aug 10, 2018	BUY	$2.88 - $8.67 $412,381 - $1.24 Million	143,188 New	143,188 $985,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $880M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.